Rebamipide Use in Children
Rebamipide is NOT approved for use in children, and there is no established pediatric dosing or safety data available for this medication. The FDA drug label information provided 1 pertains to topiramate (an antiepileptic drug), not rebamipide, indicating a data retrieval error in the evidence base.
Current Evidence Status
Lack of Pediatric Data
- No pediatric clinical trials exist for rebamipide in children
- No FDA approval for pediatric use
- No established dosing guidelines for any pediatric age group
- The available research focuses exclusively on adult populations 2, 3, 4, 5
What We Know About Rebamipide (Adult Data Only)
Rebamipide is a mucoprotective agent used primarily in adults for:
- Gastric ulcer treatment
- Chronic gastritis management
- Prevention of NSAID-induced gastrointestinal mucosal damage
- Helicobacter pylori eradication support 2, 3, 4
The drug has demonstrated excellent safety in adult populations across Southeast Asia and Russia 3, but this cannot be extrapolated to children.
Critical Pediatric Pharmacology Considerations
Why Pediatric-Specific Data Is Essential
Children are not simply "small adults" - they have fundamentally different pharmacokinetic parameters 6, 7, 8:
- Absorption varies dramatically by age, particularly in infants under 2 months
- Volume of distribution differs significantly in children under 2 years
- Hepatic metabolism is immature until approximately 6 months of age
- Renal clearance undergoes rapid maturation in the first 2 years of life 7
Weight-based dosing calculations derived from adult doses are inadequate and potentially dangerous 6. Drug clearance is highly variable and unpredictable in pediatric populations based solely on adult data.
Clinical Recommendation
Do not use rebamipide in pediatric patients until:
- Pediatric clinical trials establish safety and efficacy
- Age-specific dosing guidelines are developed
- Appropriate pediatric formulations become available
Alternative Approaches for Pediatric Gastric Protection
For gastroesophageal reflux and gastric mucosal protection in children, consider FDA-approved options 9:
- PPIs: Omeprazole, lansoprazole, esomeprazole (approved ≥1 year); rabeprazole (≥12 years)
- H2 receptor antagonists: With caution due to tachyphylaxis within 6 weeks
- These have established pediatric dosing: 0.7-3.3 mg/kg daily for omeprazole; 0.7-3.0 mg/kg daily for lansoprazole
Important Caveats
- Avoid PPI overuse in infants - placebo-controlled trials show no superiority over placebo for irritability 9
- Acid suppression in general may increase risk of community-acquired pneumonia, gastroenteritis, and candidemia in children 9
- Monitor for metabolic acidosis and growth effects with chronic acid suppression 9
The absence of pediatric data for rebamipide represents a significant knowledge gap that must be addressed through properly designed pediatric trials before this medication can be recommended for use in children 10, 6.